<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00013806</url>
  </required_header>
  <id_info>
    <org_study_id>NCRR-M01RR00240-1748</org_study_id>
    <nct_id>NCT00013806</nct_id>
  </id_info>
  <brief_title>CHP677: I-Metaiodobenzylguanidine (I-MIBG) Therapy for Refractory Neuroblastoma: a Phase II Study</brief_title>
  <official_title>CHP677: I-Metaiodobenzylguanidine (I-MIBG) Therapy for Refractory Neuroblastoma: a Phase II Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Center for Research Resources (NCRR)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Center for Research Resources (NCRR)</source>
  <brief_summary>
    <textblock>
      131I-metaiodobenzylguanidine (131I-MIBG) is a norepinephrine analog that concentrates in
      adrenergic tissue and therefore holds promise for cell-specific treatment of neuroblastoma.
      This is a dual institution, Phase II study of 131I-MIBG administered at the previously
      defined maximum practical dose of 18 mCi/kg to children with relapsed or refractory
      neuroblastoma.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <condition>Neuroblastoma</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>131I-MIBG</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria: Refractory neuroblastoma with original diagnosis based on tumor
        histopathology or elevated urine VMA with typical tumor cells in the bone marrow.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Children's Hospital of Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2003</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 29, 2001</study_first_submitted>
  <study_first_submitted_qc>March 29, 2001</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 30, 2001</study_first_posted>
  <last_update_submitted>June 23, 2005</last_update_submitted>
  <last_update_submitted_qc>June 23, 2005</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 24, 2005</last_update_posted>
  <keyword>Relapsed and refractory neuroblastoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neuroblastoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>3-Iodobenzylguanidine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

